{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:14:08Z","timestamp":1786115648625,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the relationship between residual islet \u03b2-cell function assessed by fasting C-peptide (FCP) and continuous glucose monitoring (CGM) metrics in patients with type 1 diabetes mellitus (T1DM), and to clarify the impact of residual islet \u03b2-cell function on glycemic control in T1DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted including 112 patients with T1DM [68 classic T1DM, 44 latent autoimmune diabetes in adults (LADA)] hospitalized from January 2023 to December 2025. All patients wore CGM devices for \u22657 days. Participants were stratified into four groups by FCP quartiles. Spearman correlation, restricted cubic spline (RCS) regression, and multivariable linear regression with progressive adjustment for confounders were used to evaluate associations between FCP and CGM-derived metrics, including time in range (TIR), time above range (TAR), and mean glucose (MG). Subgroup and interaction analyses were performed by diabetes subtype. Sensitivity analyses included quartile-based categorization, exclusion of LADA patients, and exclusion of those with diabetes duration \u226510 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, higher FCP levels were significantly associated with favorable CGM-derived metrics, including increased TIR, decreased TAR, and lower MG (all\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). These associations persisted after multivariable adjustment for sex, age, disease duration, BMI, insulin dosage, and glucose coefficient of variation (CV). RCS analysis revealed significant nonlinear dose-response relationships, with pronounced glycemic improvements at lower FCP concentrations and plateau effects at higher levels. LADA patients exhibited higher FCP levels, longer TIR, and lower TAR compared with classic T1DM (all\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Subgroup analyses demonstrated consistent FCP-CGM associations in both subtypes without significant interaction (all\n                      <jats:italic>P<\/jats:italic>\n                      for interaction &amp;gt; 0.05). Sensitivity analyses confirmed robust associations after excluding LADA patients or those with disease duration \u226510 years. Shorter disease duration and lower daily insulin requirements correlated with higher FCP levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Residual \u03b2-cell function is independently associated with improved CGM-derived metrics (increased TIR, decreased TAR, and lower MG) in both classic T1DM and LADA. Preserved C-peptide secretion correlates with shorter disease duration and lower daily insulin requirements. These findings highlight the importance of protecting residual \u03b2-cell function to achieve glycemic stability and reduce exogenous insulin dependence in T1DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1891725","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:32Z","timestamp":1785990272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual \u03b2-cell function is associated with continuous glucose monitoring metrics in patients with type 1 diabetes mellitus"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshuang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"Herold","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci143683","article-title":"A little help from residual \u03b2 cells has long-lasting clinical benefits","volume":"131","author":"Lam","year":"2021","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci143011","article-title":"Residual \u03b2 cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia","volume":"131","author":"Gubitosi-Klug","year":"2021","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256093","article-title":"The role of C-peptide in diabetes and its complications: an updated review","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14785","article-title":"C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective","volume":"24","author":"Maddaloni","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.01.016","article-title":"C-peptide: new findings and therapeutic possibilities","volume":"107","author":"Wahren","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0881","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial","volume":"63","author":"Lachin","year":"2014","journal-title":"Diabetes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/med.0000000000000947","article-title":"The evolution of C-peptide's role in diabetes care","volume":"33","author":"Briggs","year":"2026","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00125-018-4768-y","article-title":"Capturing residual beta cell function in type 1 diabetes","volume":"62","author":"Pociot","year":"2019","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2025.2370","article-title":"Advances in continuous glucose monitoring: clinical applications","volume":"40","author":"Kwon","year":"2025","journal-title":"Endocrinol Metab (Seoul Korea)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06171-y","article-title":"The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study","volume":"67","author":"De Meulemeester","year":"2024","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00125-025-06578-1","article-title":"Persistent C-peptide secretion is associated with favourable CGM metrics in adults with type 1 diabetes","volume":"69","author":"Stimson","year":"2026","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13098-020-00616-1","article-title":"Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation","volume":"12","author":"Fadiga","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/aitc202203150","article-title":"Type 1 diabetes mellitus","volume":"175","author":"Syed","year":"2022","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155142","article-title":"Insulin: the master regulator of glucose metabolism","volume":"129","author":"Norton","year":"2022","journal-title":"Metabolism"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108867","article-title":"Association of detectable C-peptide levels with glycemic control and chronic complications in individuals with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"39","author":"Alan","year":"2025","journal-title":"J\u00a0Diabetes Complications"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15581","article-title":"Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: an updated systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Grando Alves","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/db24-0163","article-title":"Revisiting the pattern of loss of \u03b2-cell function in preclinical type 1 diabetes","volume":"73","author":"Martino","year":"2024","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1952","article-title":"Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes","volume":"38","author":"Davis","year":"2015","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0676","article-title":"Residual insulin production and pancreatic \u00df-cell turnover after 50 years of diabetes: Joslin Medalist Study","volume":"59","author":"Keenan","year":"2010","journal-title":"Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci134057","article-title":"High residual C-peptide likely contributes to glycemic control in type 1 diabetes","volume":"130","author":"Rickels","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S343514","article-title":"The role of glucagon in glycemic variability in type 1 diabetes: a narrative review","volume":"14","author":"Guo","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05099-3","article-title":"Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes","volume":"63","author":"Gibb","year":"2020","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-024-01488-2","article-title":"A new glucose monitoring system for the intermittent monitoring of interstitial glucose values in patients with diabetes mellitus","volume":"23","author":"Rossi","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2326036","article-title":"Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes","volume":"33","author":"Maddaloni","year":"2024","journal-title":"Expert Opin Invest Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0567","article-title":"Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications","volume":"44","author":"Jeyam","year":"2021","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1306127","article-title":"TMEM219 regulates the transcription factor expression and proliferation of beta cells","volume":"15","author":"D'Addio","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1093","article-title":"Diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions","volume":"62","author":"Nathan","year":"2013","journal-title":"Diabetes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:33Z","timestamp":1785990273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1891725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1891725"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1891725","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1891725"}}